ClinicalTrials.gg
CompletedNCT00076362Updated Sep 12, 2011

Pediatric Hypothalamic Obesity

A Phase 4 interventional study of Sandostatin LAR in Obesity, sponsored by Novartis Pharmaceuticals. Completed at 15 sites in United States. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2011-09-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Obesity by Novartis — none open to participants now, none under way, none of them phase 3. Obesity · Novartis.

Enrollment
13th of 16
60 · median 116
Started
2004
the only one that year
Phase 4
5 of 16
none open now
Registered
1st of 16
by date

Among the 16 studies in Obesity by Novartis, this one is the 13th largest by enrollment, is the only one that started in 2004, is one of 5 in phase 4, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 16 studies in Obesity by Novartis is open now. The open studies under Obesity, anywhere →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Obesity by Novartis as a file.
02

Study summary

This trial is being conducted in pediatric patients with Hypothalamic Obesity. This generally occurs in people who have had an injury to or tumor in their hypothalamus (gland or organ that secretes hormones). The purpose of this trial is to see how an investigational treatment controls the hormone insulin by lowering the level of insulin in the body resulting in a weight loss in children who are at least 6 years of age but less than 18 years of age. Some children in this trial will receive placebo.

To qualify for this study, you and your child's doctor must feel that your child's weight is inadequately controlled within a year from the time of injury to the hypothalamus or tumor of the hypothalamus. This study will help to determine if an investigational treatment is of benefit in controlling a child's weight.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Male and female patients ages 6 to less than 18
  • Patients who have experienced any form of cranial insult related to cranial trauma, or to a tumor or it's treatment (i.e. surgery, radiation, and/or chemotherapy)
  • Patients who are at least one year out following therapy for their tumor
  • Patients who have severe cardiovascular dysfunction (for example cardiomyopathy, congestive heart failure ( Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation) will be excluded
  • Patients with severe neurologic handicaps which preclude normal physical activity will be excluded.
  • Patients confined to bed and those patients who are wheelchair bound which prevents them from activities of daily living or normal physical activity, i.e. walking, will be excluded from the trial
  • Your child must be greater than 120% of their ideal body weight for their height or have a that is greater than or equal to 27.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in BMI

Secondary outcomes

  1. Change from baseline in weight, leptin, insulin AUC, C-peptide AUC, amylin AUC, glucose AUC, dietary intake, physical activity, waist-to-hip ratio, visceral and subcutaneous abdominal fat

07

Study locations

15 sites
  • Phoenix Children'S Hospital
    Phoenix, Arizona 85016, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • University of California at San Francisco
    San Francisco, California 94143, United States
  • University of Colorado
    Denver, Colorado 80218, United States
  • Miami Children'S Hopital
    Miami, Florida 33155, United States
  • Childrens Memorial Hospital
    Chicago, Illinois 60614, United States
  • St. Vincent Children's Center for Cancer and Blood Diseases
    Indianapolis, Indiana 46260, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Washington University
    St. Louis, Missouri 63110, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • U of Tennessee HELP Center
    Memphis, Tennessee 38103, United States
  • UT Southwestern Children's Medical Center of Dallas
    Dallas, Texas 75390, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004 and a primary completion of Jul 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2004
First posted
Jan 23, 2004
Start
Mar 2004
Primary completionActual
Jul 2005
Last update
Sep 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00076362
Responsible party
Sponsor
First posted
Jan 23, 2004
Start date
Mar 2004
Primary completion
Jul 2005
Last update
Sep 12, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion